ATE262587T1 - Menschliche proteaseinhibitoren vom kunitztyp - Google Patents

Menschliche proteaseinhibitoren vom kunitztyp

Info

Publication number
ATE262587T1
ATE262587T1 AT95900509T AT95900509T ATE262587T1 AT E262587 T1 ATE262587 T1 AT E262587T1 AT 95900509 T AT95900509 T AT 95900509T AT 95900509 T AT95900509 T AT 95900509T AT E262587 T1 ATE262587 T1 AT E262587T1
Authority
AT
Austria
Prior art keywords
dna
human
dna segment
kunitz type
inhibitors
Prior art date
Application number
AT95900509T
Other languages
English (en)
Inventor
Cindy A Sprecher
Walt Kisiel
Donald C Foster
Original Assignee
Zymogenetics Inc
Univ New Mexico
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc, Univ New Mexico filed Critical Zymogenetics Inc
Application granted granted Critical
Publication of ATE262587T1 publication Critical patent/ATE262587T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT95900509T 1993-11-05 1994-11-02 Menschliche proteaseinhibitoren vom kunitztyp ATE262587T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/147,710 US5455338A (en) 1993-11-05 1993-11-05 DNA encoding novel human kunitz-type inhibitors and methods relating thereto
PCT/US1994/012609 WO1995012674A1 (en) 1993-11-05 1994-11-02 Human kunitz-type protease inhibitors

Publications (1)

Publication Number Publication Date
ATE262587T1 true ATE262587T1 (de) 2004-04-15

Family

ID=22522614

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95900509T ATE262587T1 (de) 1993-11-05 1994-11-02 Menschliche proteaseinhibitoren vom kunitztyp

Country Status (12)

Country Link
US (7) US5455338A (de)
EP (1) EP0726953B1 (de)
JP (1) JP3201527B2 (de)
KR (1) KR100243989B1 (de)
CN (1) CN1073159C (de)
AT (1) ATE262587T1 (de)
AU (1) AU685190B2 (de)
CA (1) CA2175797C (de)
DE (1) DE69433647T2 (de)
FI (1) FI961886L (de)
NO (1) NO961812L (de)
WO (1) WO1995012674A1 (de)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5455338A (en) * 1993-11-05 1995-10-03 Zymogenetics, Inc. DNA encoding novel human kunitz-type inhibitors and methods relating thereto
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US5795954A (en) * 1994-03-04 1998-08-18 Genentech, Inc. Factor VIIa inhibitors from Kunitz domain proteins
US5786328A (en) * 1995-06-05 1998-07-28 Genentech, Inc. Use of kunitz type plasma kallikrein inhibitors
US5780265A (en) * 1995-06-05 1998-07-14 Genentech, Inc. Kunitz type plasma kallikrein inhibitors
WO1997005893A1 (en) * 1995-08-09 1997-02-20 Toray Industries, Inc. Remedy for ophthalmic diseases
JP3469584B2 (ja) * 1996-03-11 2003-11-25 バイエル コーポレイション ヒト ビクニン
ES2209542T3 (es) * 1998-12-22 2004-06-16 Bayer Aktiengesellschaft Metodo para acelerar la velocidad de eliminacion mucociliar usando un inhibidor de serinproteasa de tipo kunitz.
US20070140979A1 (en) * 1998-12-22 2007-06-21 Bayer Aktiengesellschaft Method for accelerating the rate of mucociliary clearance
AU6893100A (en) * 1999-08-02 2001-02-19 Avigen, Inc. Use of recombinant adeno-associated virus vector (raav) for the prevention of smooth muscle cell proliferation in vascular graft
US6180607B1 (en) 1999-08-05 2001-01-30 Christopher Davies Protein having proteinase inhibitor activity
US20040235715A1 (en) * 1999-11-12 2004-11-25 Bayer Corporation Method of producing glycosylated bikunin
US6964764B2 (en) 1999-11-13 2005-11-15 Talecris Biotherapeutics, Inc. Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
US7544500B2 (en) * 1999-11-13 2009-06-09 Talecris Biotherapeutics, Inc. Process for the production of a reversibly inactive acidified plasmin composition
US6355243B1 (en) * 1999-11-13 2002-03-12 Bayer Corporation Method of thrombolysis by local delivery of active plasmin
US20020132978A1 (en) * 2000-03-21 2002-09-19 Hans-Peter Gerber VEGF-modulated genes and methods employing them
AU2001296470A1 (en) 2000-10-02 2002-04-15 Marc D. Andelman Fringe-field capacitor electrode for electrochemical device
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
ES2348230T3 (es) * 2002-06-07 2010-12-01 Dyax Corp. Prevención y reducción de la isquemia.
US7244616B2 (en) 2003-06-27 2007-07-17 Bayer Pharmaceuticals Corporation Use of molecular chaperones for the enhanced production of secreted, recombinant proteins in mammalian cells
US7910550B2 (en) * 2004-04-16 2011-03-22 Stc.Unm Human kunitz-type inhibitor with enhanced antifibrinolytic activity
US7432238B2 (en) * 2004-04-16 2008-10-07 Stc.Unm Human Kunitz-type inhibitor with enhanced antifibrinolytic activity
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
ZA200707490B (en) * 2005-03-10 2008-12-31 Genentech Inc Methods and compositions for modulatiing vascular integrity
PL1981519T3 (pl) 2005-12-29 2018-07-31 Dyax Corp. Hamowanie proteaz
EP3088522B1 (de) 2005-12-29 2017-11-29 The Regents of the University of California Verfahren und zusammensetzungen in verbindung mit mutanter kunitz-domäne i von tfpi-2
US20070278239A1 (en) * 2006-05-17 2007-12-06 Michele Vogt Sipping lid closure device and method of use
US20090075887A1 (en) * 2007-08-21 2009-03-19 Genzyme Corporation Treatment with Kallikrein Inhibitors
DE102007056231A1 (de) 2007-09-08 2009-03-12 Bayer Healthcare Ag Herstellung und Verwendung von Varianten humander Kunitz-Typ Protease-Inhibitoren (hKTPI)
EP2915564B1 (de) 2007-09-28 2020-11-04 Portola Pharmaceuticals, Inc. Gegenmittel für Faktor-XA-Hemmer und Verfahren zur Verwendung davon
WO2009149199A2 (en) * 2008-06-04 2009-12-10 Talecris Biotherapeutics, Inc. Composition, method and kit for preparing plasmin
KR101792032B1 (ko) 2008-12-19 2017-11-02 백스터 인터내셔널 인코포레이티드 Ｔｆｐｉ 억제제 및 사용 방법
WO2010072691A1 (en) 2008-12-22 2010-07-01 Novo Nordisk A/S Antibodies against tissue factor pathway inhibitor
US8637454B2 (en) * 2009-01-06 2014-01-28 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
PT2403865E (pt) 2009-03-03 2015-11-18 Grifols Therapeutics Inc Métodos de preparação de plasminogénio
EP3121271B1 (de) 2009-03-30 2019-07-24 Portola Pharmaceuticals, Inc. Gegenmittel für faktor-xa-hemmer und verfahren zur verwendung davon
CN101588509B (zh) * 2009-06-23 2011-08-24 硅谷数模半导体（北京）有限公司 视频图像编码和解码方法
ES2605801T3 (es) 2009-07-15 2017-03-16 Portola Pharmaceuticals, Inc. Formulación de dosis unitaria de antídoto para inhibidores del factor Xa para su uso en la prevención de la hemorragia
SMT201800552T1 (it) 2010-01-06 2018-11-09 Dyax Corp Proteine che legano la callicreina plasmatica
PT3345615T (pt) 2010-03-01 2020-01-17 Bayer Healthcare Llc Anticorpos monoclonais otimizados contra inibidor da via do fator tecidual (tfpi)
DK2547355T3 (en) 2010-03-19 2017-03-20 Baxalta GmbH TFPI INHIBITORS AND METHODS OF USE
KR102320178B1 (ko) 2011-01-06 2021-11-02 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질
US11448657B2 (en) * 2011-01-18 2022-09-20 Rambam Med-Tech Methods and kits for assessing Heparanase procoagulant activity, compositions comprising Heparanase, and methods for the treatment of coagulation-related disorders
WO2013016449A2 (en) 2011-07-26 2013-01-31 Indicator Systems International, Inc. Assays for the detection of microbes
CA2867444C (en) 2012-03-16 2021-04-13 University Health Network Compositions containing soluble toso protein and uses thereof
BR112014022435B1 (pt) 2012-03-21 2023-02-14 Takeda Pharmaceutical Company Limited Inibidores de tfpi e métodos de uso
EP2970434B1 (de) * 2013-03-15 2018-12-05 The Regents of The University of California Potenter kunitz-inhibitor der fibrinolyse mit dualer reaktivität
AU2015225867B2 (en) 2014-03-07 2020-02-06 University Health Network Methods and compositions for modifying the immune response
US10428158B2 (en) 2014-03-27 2019-10-01 Dyax Corp. Compositions and methods for treatment of diabetic macular edema
US10287338B2 (en) 2015-07-10 2019-05-14 Miran NERSISSIAN Factor VIII protein compositions and methods of treating of hemophilia A
WO2017023863A1 (en) 2015-07-31 2017-02-09 Research Institute At Nationwide Children's Hospital Peptides and antibodies for the removal of biofilms
EP3365027B1 (de) 2015-10-14 2022-03-30 Research Institute at Nationwide Children's Hospital Hu-spezifische antikörper und deren verwendeng zur hemmung von biofilm
EP3387018A1 (de) 2015-12-11 2018-10-17 Dyax Corp. Plasma-kallikrein-inhibitoren und verwendungen davon zur behandlung von hereditärem angioödem
US11564982B2 (en) 2017-01-04 2023-01-31 Research Institute At Nationwide Children's Hospital DNABII vaccines and antibodies with enhanced activity
JP7661008B2 (ja) 2017-01-04 2025-04-14 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル バイオフィルム関連障害の処置のための抗体断片
WO2018170178A1 (en) 2017-03-15 2018-09-20 Research Institute At Nationwide Children's Hospital Composition and methods for disruption of bacterial biofilms without accompanying inflammation
AU2020311897A1 (en) 2019-07-08 2022-02-03 Research Institute At Nationwide Children's Hospital Antibody compositions for disrupting biofilms
EP4090427A1 (de) 2020-01-13 2022-11-23 Takeda Pharmaceutical Company Limited Plasma-kallikrein-inhibitoren und verwendungen davon zur pädiatrischen behandlung von hereditärem angioödem
CN112206310B (zh) * 2020-09-23 2022-10-21 湖北医药学院 一组用于抑制补体的寄生绦虫多肽

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES8702431A1 (es) * 1984-09-21 1986-12-16 Boehringer Ingelheim Int Procedimiento para preparar una proteina inhibidora de la coagulacion de la sangre
US5011912A (en) * 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US5106833A (en) * 1987-07-23 1992-04-21 Washington University Coagulation inhibitors
IL87171A (en) * 1987-11-23 1995-08-31 Monsanto Co cDNA of human tissue factor inhibitor
DK408089D0 (da) * 1989-08-18 1989-08-18 Novo Nordisk As Proteiner
US5557518A (en) * 1994-04-28 1996-09-17 Citibank, N.A. Trusted agents for open electronic commerce
IL104324A0 (en) * 1992-01-07 1993-05-13 Novo Nordisk As Variant of human kunitz-type protease inhibitor
IL104325A (en) * 1992-01-07 2000-10-31 Novo Nordisk As Variants of human kunitz-type protease inhibitor domain II of tissue factor pathway inhibitor (TFPI) pharmaceutical compositions containing them a DNA construct encoding them their expression vectors a cell containing said DNA constructs and methods for the production of all the above
US5276015A (en) * 1992-03-18 1994-01-04 Washington University Method of inhibiting microvascular thrombosis
US5884292A (en) * 1993-05-06 1999-03-16 Pitney Bowes Inc. System for smart card funds refill
US5455338A (en) * 1993-11-05 1995-10-03 Zymogenetics, Inc. DNA encoding novel human kunitz-type inhibitors and methods relating thereto
US5578808A (en) * 1993-12-22 1996-11-26 Datamark Services, Inc. Data card that can be used for transactions involving separate card issuers
US5854975A (en) * 1994-12-23 1998-12-29 Freedom Wireless, Inc. Prepaid security cellular telecommunications system
US5722067A (en) * 1994-12-23 1998-02-24 Freedom Wireless, Inc. Security cellular telecommunications system
US5903633A (en) * 1995-03-27 1999-05-11 Smarttalk Teleservices, Inc. Method and apparatus for prepaid phone card activation and billing
US5684291A (en) * 1995-06-01 1997-11-04 American Express Trs Refundable prepaid telephone card
US5778313A (en) * 1995-12-08 1998-07-07 Cellexis International, Inc. Pre-paid cellular telephone system
US5892827A (en) * 1996-06-14 1999-04-06 Catalina Marketing International, Inc. Method and apparatus for generating personal identification numbers for use in consumer transactions
US5845259A (en) * 1996-06-27 1998-12-01 Electronic Consumer Concepts, L.L.C. Electronic coupon dispensing system
US5991749A (en) * 1996-09-11 1999-11-23 Morrill, Jr.; Paul H. Wireless telephony for collecting tolls, conducting financial transactions, and authorizing other activities
US5828740A (en) * 1996-11-14 1998-10-27 Sprint Communications Co., L.P. Prepaid calling card external/adjunct database processor
US5991380A (en) * 1997-10-21 1999-11-23 At&T Corp. Universal telecommunications services account
US6035025A (en) * 1998-01-07 2000-03-07 National Telemanagement Corporation System and method for a prepaid bundled telecommunications account
US7249054B2 (en) * 1998-06-18 2007-07-24 Keil Dean S System and method for debit account transactions
EP1105813A4 (de) * 1998-08-25 2001-10-10 Mobshop Inc On-line marketing system und verfahren
US20030163425A1 (en) * 2002-02-26 2003-08-28 Cannon Thomas Calvin System for executing high-volume electronic bill payments

Also Published As

Publication number Publication date
DE69433647D1 (de) 2004-04-29
KR960705850A (ko) 1996-11-08
NO961812L (no) 1996-07-05
US5455338A (en) 1995-10-03
US20050004021A1 (en) 2005-01-06
CA2175797C (en) 2000-07-18
US7541449B2 (en) 2009-06-02
US20020098560A1 (en) 2002-07-25
US20040253686A1 (en) 2004-12-16
EP0726953B1 (de) 2004-03-24
FI961886A7 (fi) 1996-07-03
EP0726953A1 (de) 1996-08-21
CN1073159C (zh) 2001-10-17
CA2175797A1 (en) 1995-05-11
AU685190B2 (en) 1998-01-15
US5914315A (en) 1999-06-22
FI961886L (fi) 1996-07-03
NO961812D0 (no) 1996-05-03
US20070092948A1 (en) 2007-04-26
JPH09504696A (ja) 1997-05-13
US6656746B2 (en) 2003-12-02
DE69433647T2 (de) 2004-08-05
JP3201527B2 (ja) 2001-08-20
FI961886A0 (fi) 1996-05-03
KR100243989B1 (ko) 2000-02-01
WO1995012674A1 (en) 1995-05-11
US5728674A (en) 1998-03-17
CN1139955A (zh) 1997-01-08
AU8131294A (en) 1995-05-23

Similar Documents

Publication Publication Date Title
ATE262587T1 (de) Menschliche proteaseinhibitoren vom kunitztyp
WO1994012637A3 (en) Novel human amyloid protein precursor homologue and kunitz-type inhibitors
YU8997A (sh) Prečišćen protein koji ima serinsku proteaznu inhibitorsku aktivnost i farmaceutski preparat koji ga sadrži
FI934811A0 (fi) Stabiliserade enzymer och detergentfoereningar
NO962188L (no) Nye apoptose-modulerende proteiner, DNA som koder for proteinene og fremgangsmåter for anvendelse derav
PT737207E (pt) Inibidores de plasmina humana derivados de dominios kunitz
NO964598D0 (no) Angiostatin og fremgangsmåte for anvendelse i inhibering av angiogenese
DE3587875D1 (de) Rekombinantverfahren zur herstellung von serinproteaseinhibitoren, sowie dns-sequenzen dazu.
DK0804558T3 (da) Tripeptidylaminopeptidase
NO974035D0 (no) En ny vestfaktor og en genetisk sekvens som koder for denne
ATE264913T1 (de) Protease-resistente analoge des thrombomodulin
ATE224443T1 (de) Mch2, eine apoptotische cystein-protease, zusammensetzungen für ihre präparation und methoden für ihre verwendung
ATE208821T1 (de) Klonierung und expression von genen, kodierend für enzyme aus pilzen, die arabinan abbauen
GB0123664D0 (en) Histone deacetylase 9
NO972313L (no) Peptider som er i stand til å binde til GAP-protein-SH3-området, nukleotid-sekvenser som koder for dette samt fremstilling og bruk derav
MX9702776A (es) Proteinas de proteasa de pulgas, moleculas de acido nucleico, y usos de las mismas.
DE69433385D1 (de) Für die untereinheiten der 1,3-beta-d-glucansynthase kodierende dna
DK0877758T3 (da) Oprenset SR-p70-protein
FI943146A0 (fi) Signaalipeptideistä vapaiden stafylokinaasien ilmentyminen
IE902276L (en) Serpin variants
BR0107655A (pt) Polinucleotìdeo isolado, vetor de expressão recombinante, polipeptìdeo, célula, método para produzir o polipeptìdeo, e, composição farmacêutica
BR9815277A (pt) Fragmento de ácido nucléico isolado, gene quimérico, célula hospedeira transformada, homólogo de soja, método para alterar o nìvel de expressão de um homólogo do ativador de transcrição pvalf de phaseolus vulgaris em uma célula vegetal, método de obtenção de um fragmento de ácido nucléico e produto
DE60030884D1 (de) Transkriptionsfaktoren welche zwei potentielle dna bindende motive enthalten
DK1005532T3 (da) Isolerede nukleinsyremolekyler kodende for SSX familiemedlemmer og anvendelser deraf
WO1995003333A3 (en) Tryptase inhibitor

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties